Technology
Health
Biotechnology
Voyager Therapeutics
$18.099876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$18.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.32 (-1.74%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell VYGR and other stocks, options, ETFs, and crypto commission-free!
About
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. Read More The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
Employees
123
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
595.84M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
424.20K
High Today
$18.55
Low Today
$17.91
Open Price
$18.19
Volume
166.43K
52 Week High
$24.24
52 Week Low
$7.76
Collections
Technology
Health
Biotechnology
Therapy
Medical
2015 IPO
US
North America
News
MarketBeatFeb 28
Stock Price, News, & Analysis for Voyager Therapeutics
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program, for tauopath...
Yahoo FinanceFeb 25
AbbVie Extends Deal With Voyager to Make Parkinson's Drugs
AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.
MarketWatchFeb 22
Voyager Therapeutics stock soars after AbbVie collaboration potentially valued at over $1 billion
Shares of Voyager Therapeutics Inc. VYGR, -1.93% ran up 14.2% in premarket trade Friday, after the gene therapy company and AbbVie Inc. ABBV, -1.55% announced a collaboration to develop antibodies to treat Parkinson's disease. AbbVie's stock was still inactive ahead of the open. Under terms of the collaboration, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential milestone payments and royalties....
Price Paid on Robinhood
14% Higher
Right Now
52 Week Low
$7.76
Average Price Paid
$15.90
52 Week High
$24.24
Earnings
-$0.89
-$0.65
-$0.40
-$0.16
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 9, After Hours